Would you trust a drug approved using virtual patients? The FDA is building the framework that could make it possible
Digital twins and model-informed drug development are moving from research concepts toward regulatory infrastructure, raising the possibility that future pharmaceutical trials could use simulated patients to refine doses, predict outcomes and potentially reduce the number of people required in selected control groups.